The global cardiac troponin market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Cardiac troponins are known as cardiac biomarkers, also known as diagnostic markers, that are used as indicators of myocardial infarction. Cardiac troponin is found in skeletal muscles, and cardiac muscles of humans and increased levels of cardiac troponin circulating in the blood represents the onset of myocardial infarction. The market growth is majorly attributed owing to the growing prevalence of acute coronary syndrome, the rising number of cases of myocardial infarction, and thus, the need to diagnose CVD. As per the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of mortalities globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all the mortalities globally. Further, out of the 17 million premature mortalities (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs.

Further, as per the American Heart Association (AHA), in the US, the total cost of heart-associated health expenditure is valued at more than $100 billion on an average, of which 70% is due to hospitalization. These stats call out for a novel approach that fosters the diagnosis of CVDs and thus, the reduction in the burden of healthcare costs due to faster and acute diagnosis. This factor is further anticipated to provide a boost to the overall market growth.

Some key players operating in the market include F. Hoffmann La-Roche AG, Abbott Laboratories, and Siemens Healthcare GmbH, among others. These players are fousing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in June 2018, Beckman Coulter Diagnostics received Health Canada clearance for its new high sensitivity troponin (hsTnI) assay, Access hsTnI, that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

 o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  F. Hoffmann La-Roche AG, Abbott Laboratories, and Siemens Healthcare GmbH, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Cardiac Troponin Market Report by Segment

By Type

    • Troponin I

    • Troponin T 

    • Others

By Application

    • Acute Coronary Syndrome

    • Myocardial Infarction

    • Congestive Heart Failure

    • Others

Global Cardiac Troponin Market by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa